This project combines genomic, metagenomics and metabolic research and aims to better understand the pathophysiology of diabetes and find new therapies. We aim to investigate the role of gut microbiota in response to drug action in people living with prediabetes and type 2 diabetes. The role of gut microbiota on the efficacy of diabetic drugs has not previously been extensively studied and the project therefore aims to open up a new avenue of tailored diabetes treatment.